Uterine bleeding with hormone therapies in menopausal women: a systematic review

References

• The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017;24:728–53
   PubMed Web of Science ®Google Scholar
• Archer DF. Endometrial bleeding in postmenopausal women: with and without hormone therapy. Menopause 2011;18:416–20
   PubMed Web of Science ®Google Scholar
• Arbuckle R, Humphrey L, Abraham L, et al. Qualitative cross-cultural exploration of vaginal bleeding/spotting symptoms and impacts associated with hormone therapy in post-menopausal women to inform the development of new patient-reported measurement tools. Maturitas 2014;78:219–27
   PubMed Web of Science ®Google Scholar
• Newton KM, Reed SD, Nekhyludov L, et al. Factors associated with successful discontinuation of hormone therapy. J Womens Health (Larchmt) 2014;23:382–8
   PubMed Web of Science ®Google Scholar
• Welton AJ, Vickers MR, Kim J, et al. Health related quality of life after combined hormone replacement therapy: randomised controlled trial. BMJ 2008;337:a1190–a1190
   PubMed Web of Science ®Google Scholar
• Munro MG, Southern California Permanente Medical Group's Abnormal Uterine Bleeding Working Group. Investigation of women with postmenopausal uterine bleeding: clinical practice recommendations. Perm J 2014;18:55–70
   PubMedGoogle Scholar
• Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 2007;24:37–55
   PubMed Web of Science ®Google Scholar
• Archer DF, Dorin MH, Heine W, Nanavati N, Arce JC. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group. Obstet Gynecol 1999;94:323–9
   PubMed Web of Science ®Google Scholar
• Yildirim G, Tugrul S, Uslu H, Pekin O, Eren S. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding. Arch Gynecol Obstet 2006;273:268–73
   PubMedGoogle Scholar
• Hammar ML, van de Weijer P, Franke HR, Pornel B, von Mauw EM, Nijland EA. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. BJOG 2007;114:1522–9
   PubMed Web of Science ®Google Scholar
• Samsioe G, Dvorak V, Genazzani AR, et al. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. Maturitas 2007;57:171–81
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Schmelter T, Schaefers M, Gerlinger C, Gude K. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women. Climacteric 2013;16:490–8
   PubMed Web of Science ®Google Scholar
• Bouchard P, De Cicco-Nardone F, Spielmann D, Garcea N, Trimegestone 3, Study G. Bleeding profile and endometrial safety of continuous combined regimens 1 mg 17beta-estradiol/trimegestone versus 1 or 2 mg 17beta-estradiol/norethisterone acetate in postmenopausal women. Gynecol Endocrinol 2005;21:142–8
   PubMed Web of Science ®Google Scholar
• Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. BJOG 1998;105:904–11
   Web of Science ®Google Scholar
• Mattsson LA, Bohnet HG, Gredmark T, Torhorst J, Hornig F, Hüls G. Continuous, combined hormone replacement: randomized comparison of transdermal and oral preparations. Obstet Gynecol 1999;94:61–5
   PubMed Web of Science ®Google Scholar
• Doren M, Rubig A, Bennink C, Holzgreve HJ. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999;6:299–306
   PubMed Web of Science ®Google Scholar
• Graser T, Koytchev R, Muller A, Oettel M. Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and kliogest for continuous combined hormone replacement therapy in postmenopausal women. Climacteric 2000;3:109–18
   PubMedGoogle Scholar
• Rozenberg S, Caubel P, Lim PC. Constant estrogen, intermittent progestogen vs. continuous combined hormone replacement therapy: tolerability and effect on vasomotor symptoms. Int J Gynaecol Obstet 2001;72:235–43
   PubMed Web of Science ®Google Scholar
• Odmark IS, Jonsson B, Backstrom T. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17beta-estradiol and norethindrone acetate. Am J Obstet Gynecol 2001;184:1131–8
   PubMed Web of Science ®Google Scholar
• Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716–27
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Durand G, Kahler E, Pertynski T. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17beta-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study. Maturitas 2010;67:227–32
   PubMed Web of Science ®Google Scholar
• Pickar JH, Bottiglioni F, Archer DF. Amenorrhea frequency with continuous combined hormone replacement therapy: a retrospective analysis. Menopause Study Group. Climacteric 1998;1:130–6
   PubMedGoogle Scholar
• Archer DF, Pickar JH. Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding. Obstet Gynecol 2000;96:899–905
   PubMed Web of Science ®Google Scholar
• Baracat EC, Barbosa IC, Giordano MG, et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 2002;5:60–9
   PubMed Web of Science ®Google Scholar
• Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomised comparison of low and standard doses. J Br Menopause Soc 2004;10:95–102
   PubMedGoogle Scholar
• Mattsson LA, Skouby S, Rees M, et al. Efficacy and tolerability of continuous combined hormone replacement therapy in early postmenopausal women. Menopause Int 2007;13:124–31
   PubMedGoogle Scholar
• Shulman LP, Yankov V, Uhl K. Safety and efficacy of a continuous once-a-week 17á-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause 2002;9:195–207
   PubMed Web of Science ®Google Scholar
• Archer DF, Furst K, Tipping D, Dain MP, Vandepol C. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999;94:498–503
   PubMed Web of Science ®Google Scholar
• Ylikorkala O, Rozenberg S. Efficacy and tolerability of fully transdermal hormone replacement in sequential or continuous therapy at two doses of progestogen in postmenopausal women. Maturitas 2000;37:83–93
   PubMed Web of Science ®Google Scholar
• Oosterbaan HP, van Buuren AH, Schram JH, et al. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. Maturitas 1995;21:211–19
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Teter P, Lees B. 17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women. Maturitas 2001;38:197–203
   PubMed Web of Science ®Google Scholar
• AinMelk Y. Comparison of two continuous combined estrogen progestogen regimens in postmenopausal women: a randomized trial. Fertil Steril 1996;66:962–8
   PubMed Web of Science ®Google Scholar
• Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994;83:686–92
   PubMed Web of Science ®Google Scholar
• Jirapinyo M, Theppisai U, Manonai J, Suchartwatnachai C, Jorgensen LN. Effect of combined oral estrogen/progestogen preparation (kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naive Thai women. Acta Obstet Gynecol Scand 2003;82:857–66
   PubMed Web of Science ®Google Scholar
• Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080–7
   PubMed Web of Science ®Google Scholar
• Mirkin S, Komm BS, Pan K, Chines AA. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climacteric 2013;16:338–46
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014;99:E189–E98
   PubMed Web of Science ®Google Scholar
• Kagan R, Abreu P, Andrews E. Vaginal bleeding/spotting with conjugated estrogens/bazedoxifene, conjugated estrogens/medroxyprogesterone acetate, and placebo. Postgrad Med 2018;130:687–93
   PubMed Web of Science ®Google Scholar
• Simon JA, Liu JH, Speroff L, Shumel BS, Symons JP. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Am J Obstet Gynecol 2003;188:92–9
   PubMed Web of Science ®Google Scholar
• Kazerooni T, Zolghadri J. The comparison of bleeding patterns with high-dose and low-dose hormone replacement therapy in postmenopausal women. Gynecol Endocrinol 2004;19:64–8
   PubMed Web of Science ®Google Scholar
• Barnabei VM, Cochrane BB, Aragaki AK, et al. Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative. Obstet Gynecol 2005;105:1063–73
   PubMed Web of Science ®Google Scholar
• Rowan JP, Simon JA, Speroff L, Ellman H. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. Clin Ther 2006;28:921–32
   PubMed Web of Science ®Google Scholar
• Brynhildsen J, Hammar M. Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. Menopause 2002;9:137–44
   PubMed Web of Science ®Google Scholar
• Limpaphayom KK, Bunyavejchevin S. Clinical effects of 17 beta-estradiol and norethisterone acetate in postmenopausal Thai women. J Med Assoc Thai 2000;83:410–17
   Google Scholar
• Mirkin S, Goldstein SR, Archer DF, Pickar JH, Graham S, Bernick B. Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR). Menopause 2020;27:410–7
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Pornel B, Koninckx PR, Palacios S, Christiansen C. Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol norethisterone regimen. Hum Reprod 2009;24:1739–47
   PubMed Web of Science ®Google Scholar
• Haines CJ, Chung TK, Lau TK. Sonographic measurement of endometrial thickness as a predictor of vaginal bleeding in women using continuous combined hormone replacement therapy. Gynecol Obstet Invest 1997;44:187–90
   PubMed Web of Science ®Google Scholar
• Bassol S, Carranza-Lira S, Celis-Gonzalez C, et al. The impact of a monophasic continuous estro-progestogenic treatment on Latin American menopausal women. Maturitas 2005;50:189–95
   PubMed Web of Science ®Google Scholar
• Quereux C, Pornel B, Bergeron C, Ferenczy A. Continuous combined hormone replacement therapy with 1 mg 17beta-oestradiol and 5 mg dydrogesterone (Femoston-conti): endometrial safety and bleeding profile. Maturitas 2006;53:299–305
   PubMed Web of Science ®Google Scholar
• Graser T, Romer T, Wiedey KD, Janaud A. Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints. Climacteric 2001;4:332–42
   PubMedGoogle Scholar
• Mattsson LA, Ipsen HE, Granqvist CJ, Kokot-Kierepa M, Study G. Ultra-low-dose estradiol and norethisterone acetate: bleeding patterns and other outcomes over 52 weeks of therapy. Climacteric 2015;18:419–25
   PubMed Web of Science ®Google Scholar
• Bergeron C, Nogales FF, Rechberger T, Tatarchjuk T, Zipfel L. Ultra low dose continuous combined hormone replacement therapy with 0.5mg 17beta-oestradiol and 2.5mg dydrogesterone: protection of the endometrium and amenorrhoea rate. Maturitas 2010;66:201–5
   PubMed Web of Science ®Google Scholar
• Bijuva® (estradiol and progesterone) capsules, for oral use Prescribing Information. Boca Raton, FL: TherapeuticsMD; 2019
   Google Scholar
• TherapeuticsMD. Data on file; 2019
   Google Scholar
• Activella® (estradiol/norethindrone acetate) tablets. Princeton, NJ: Novo Nordisk Inc; 2006
   Google Scholar
• Kliovance (1 mg/0.5 mg film-coated tablets) summary of product characteristics. Gatwich, UK: Novo Nordisk Limited; 2016
   Google Scholar
• Kliofem (film-coated tablets) summary of product characteristics. Gatwich, UK: Novo Nordisk Limited; 2016
   Google Scholar
• Angeliq® (drospirenone and estradiol) tablets, for oral use Prescribing Information. Bayer Healthcare. Whippany, NJ; 2005
   Google Scholar
• Angeliq (film-coated tablets) summary of product characteristics. Bayer plc; 2018
   Google Scholar
• Prempro™/Premphase® (conjugated estrogens/medroxyprogesterone acetate tablets) Prescribing Information. Wyeth Pharmaceuticals Inc. Philadelphia, PA. 2008
   Google Scholar
• Climodien (2 mg/2mg coated tablets) summary of product characteristics. Berlin, Germany: Bayer Pharma; 2017
   Google Scholar
• Climara Pro® (estradiol/Levonorgestrel transdermal system) Prescribing Information. Northridge, CA; 3M Drug Delivery Systems; 2007
   Google Scholar
• Evorel conti summary of product characteristics. London, UK: Theramex UK Unlimited; 2019
   Google Scholar
• Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448–54
   PubMed Web of Science ®Google Scholar
• Mirkin S, Archer DF, Taylor HS, Pickar JH, Komm BS. Differential effects of menopausal therapies on the endometrium. Menopause 2014;21:899–908
   PubMed Web of Science ®Google Scholar
• Mirkin S, Navarro F, Archer DF. Hormone therapy and endometrial angiogenesis. Climacteric 2003;6:273–7
   PubMed Web of Science ®Google Scholar
• Mirkin S, Wong BC, Archer DF. Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril 2005;84:485–91
   PubMed Web of Science ®Google Scholar
• Mirkin S, Archer DF. Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, progesterone, and 17beta-estradiol on thrombospondin-1 mRNA in Ishikawa cells. Fertil Steril 2004;82:220–2
   PubMed Web of Science ®Google Scholar
• Perry W, Wiseman RA, Cullen NM. Combined oral estradiol valerate-norethisterone treatment over three years in postmenopausal women. 1. Clinical aspects and endometrial histology. Gynecol Endocrinol 1998;12:109–22
   PubMed Web of Science ®Google Scholar
• von Holst T, Lang E, Winkler U, Keil D. Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. Maturitas 2002;43:265–75
   PubMed Web of Science ®Google Scholar
• Rouskova D, Mittmann K, Schumacher U, Dietrich H, Zimmermann T. Effectiveness, tolerability and acceptance of an oral estradiol/levonorgestrel formulation for the treatment of menopausal complaints: a non-interventional observational study over six cycles of 28 days. Gynecol Endocrinol 2014;30:712–16
   PubMed Web of Science ®Google Scholar